Lilly Amyvid Lawsuit: CMS Used Tougher Standard For Alzheimer's Scan
This article was originally published in The Pink Sheet Daily
Executive Summary
A lawsuit filed by Medicare beneficiaries with support from the manufacturer of the imaging agent says diagnostic scans should not be required to show change in disease management or outcomes for Medicare coverage. CMS limits coverage to use as part of a clinical trial – and only one trial has been approved.
You may also be interested in...
Medicare And Alzheimer’s Drugs: Recent NCDs Mainly Omit Research Requirement, Biogen Notes
Biogen suggests potential precedents in past coverage decisions for upcoming Medicare determination on Aduhelm and other amyloid-directed monoclonal antibodies during earnings call.
Alzheimer's Prevention: The Next Big Idea For Fixing Drug Trial Failures
Mass screening of asymptomatic people is an expensive, daunting proposition, but very preliminary research with an amyloid beta blood test is spurring hope that a more practical way to identify those at risk will emerge in the future.
Alzheimer’s R&D In Brief: Roche’s Crenezumab Misses Endpoints, Novartis Plans Large New Genetic Study
In data presented at the Alzheimer's Association International Conference in Copenhagen, held July 12-17, Roche’s anti-amyloid beta antibody misses endpoints in two Phase II studies, but there were some promising signs of efficacy.